<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Covance Inc.</title>
	<atom:link href="http://www.stockbloghub.com/tag/covance-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Tue, 22 May 2012 18:53:06 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(CVD) Big Pharmaceutical Companies Outsourcing Research and Development</title>
		<link>http://www.stockbloghub.com/2010/10/17/cvd-big-pharmaceutical-companies-outsourcing-research-and-development/55233</link>
		<comments>http://www.stockbloghub.com/2010/10/17/cvd-big-pharmaceutical-companies-outsourcing-research-and-development/55233#comments</comments>
		<pubDate>Mon, 18 Oct 2010 03:42:59 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Research Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[Covance Inc.]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[CVD]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ICLR]]></category>
		<category><![CDATA[ICON plc]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Pharmaceutical Product Development Inc]]></category>
		<category><![CDATA[PPDI]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[WuXi PharmaTech (Cayman) Inc]]></category>
		<category><![CDATA[WX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=55233</guid>
		<description><![CDATA[by Tony D’Altorio, Investment U Research Thursday, October 14, 2010 Big pharmaceutical companies seem to be taking tips from an unlikely source these days. A decade ago, big mining companies had a big problem on their hands in the form of declining prices. With less incoming funds to spend on finding new deposits, they started thinking creatively… They let small entrepreneurial companies handle early-stage exploration, a difficult task in remote parts of the world. Then, if those operations struck it rich, the big miners swooped in to buy them out. Drug development might not seem like it has much in common with such ventures. But it involves the same high-risk, high reward discovery efforts. So the pharmaceuticals are going for the gold as well with this new approach. Cutting back ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/17/cvd-big-pharmaceutical-companies-outsourcing-research-and-development/55233/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CRL) Charles River Announces Deal to Buy China’s WuXi</title>
		<link>http://www.stockbloghub.com/2010/05/11/crl-charles-river-announces-deal-to-buy-china%e2%80%99s-wuxi/36729</link>
		<comments>http://www.stockbloghub.com/2010/05/11/crl-charles-river-announces-deal-to-buy-china%e2%80%99s-wuxi/36729#comments</comments>
		<pubDate>Tue, 11 May 2010 21:56:22 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[Covance Inc.]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[CVD]]></category>
		<category><![CDATA[Pharmaceutical Product Development Inc]]></category>
		<category><![CDATA[PPDI]]></category>
		<category><![CDATA[WuXi PharmaTech (Cayman) Inc]]></category>
		<category><![CDATA[WX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=36729</guid>
		<description><![CDATA[If you’re a healthcare stocks junkie, you may have caught the news… U.S. clinical research company Charles River Laboratories International (NYSE: CRL) announced a deal to buy its Chinese rival, WuXi PharmaTech ADR (NYSE: WX). The $1.6 billion cash-and-stock deal includes each WuXi ADR receiving $11.25 in cash and $10 of Charles’ common stock. For all intents and purposes, it seems like a good match. Charles River is one of the world’s largest research groups to develop drugs for large pharmaceutical companies to test in humans. And WuXi is one of the biggest Chinese clinical research organizations. It also makes molecules to synthesize drugs, among other things. According to Dealogic, this proposed deal ranks in the top three foreign takeovers of a Chinese company. And it is the largest outside ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/11/crl-charles-river-announces-deal-to-buy-china%e2%80%99s-wuxi/36729/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(DCTH) The Decade of Biotech: Two Hot Biotech Sectors and Eight Ways to Profit</title>
		<link>http://www.stockbloghub.com/2010/04/29/dcth-the-decade-of-biotech-two-hot-biotech-sectors-and-eight-ways-to-profit/35446</link>
		<comments>http://www.stockbloghub.com/2010/04/29/dcth-the-decade-of-biotech-two-hot-biotech-sectors-and-eight-ways-to-profit/35446#comments</comments>
		<pubDate>Thu, 29 Apr 2010 14:13:04 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AFFX]]></category>
		<category><![CDATA[Affymetrix Inc]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[Covance Inc.]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[CVD]]></category>
		<category><![CDATA[DCTH]]></category>
		<category><![CDATA[Delcath Systems Inc.]]></category>
		<category><![CDATA[Illumina Inc]]></category>
		<category><![CDATA[ILMN]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[Pharmaceutical Product Development Inc]]></category>
		<category><![CDATA[PPDI]]></category>
		<category><![CDATA[SIAL]]></category>
		<category><![CDATA[Sigma-Aldrich Corporation]]></category>
		<category><![CDATA[WuXi PharmaTech (Cayman) Inc]]></category>
		<category><![CDATA[WX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=35446</guid>
		<description><![CDATA[I expect the 2010s to be the “Decade of Biotech.” In 2020, we’ll look back at the past 10 years in amazement at how many medical advances were achieved. And we’ll likely snicker at some of the prehistoric methods that are currently used, equating them to when doctors used to perform lobotomies on people with mental problems. By 2020, there will be new drugs on the market and technologies developed that weren’t even dreamed about at the turn of the 21st century. New discoveries will extend life, or cure diseases that even the most forward-thinking scientists couldn’t have imagined just a short time ago. And fortunes will be made as a result. The question is: How do you grab your piece of the pie? Blasting Tumors… Bagging Profits If you’re ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/29/dcth-the-decade-of-biotech-two-hot-biotech-sectors-and-eight-ways-to-profit/35446/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PFWD) Phase Forward Completes Acquisition of Covance</title>
		<link>http://www.stockbloghub.com/2009/08/31/pfwd-phase-forward-completes-acquisition-of-covance/13954</link>
		<comments>http://www.stockbloghub.com/2009/08/31/pfwd-phase-forward-completes-acquisition-of-covance/13954#comments</comments>
		<pubDate>Mon, 31 Aug 2009 21:12:58 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Business Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[Covance Inc.]]></category>
		<category><![CDATA[CVD]]></category>
		<category><![CDATA[PFWD]]></category>
		<category><![CDATA[Phase Forward Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13954</guid>
		<description><![CDATA[Phase Forward (PFWD) recently announced that it completed its previously announced acquisition of the Interactive Voice and Web Response Services business of Covance Inc. (CVD) for $10 million in cash. Headquartered in Princeton, New Jersey, Phase Forward is a leading provider of data management solutions for clinical trials and drug safety. As part of the agreement, Phase Forward and Covance also entered into a multiyear marketing agreement. Management expects that this acquisition will strengthen its Interactive Response Technology solutions. Earlier, the company reported second quarter results, which beat analysts’ expectations and trimmed its outlook for 2009. Management stated that it expects revenues between $214.5 and $217.5 million. On a non-GAAP basis, the company projects EPS between 47 cents and 50 cents, down from the average forecast of 54 cents and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/31/pfwd-phase-forward-completes-acquisition-of-covance/13954/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

